Story

Collegium Pharmaceutical Stock Tumbles After Cutting Revenue Forecast

ENTHMSVIIDZHZH-TWJAKOHI
Aug 6, 20261 min read
Collegium Pharmaceutical Stock Tumbles After Cutting Revenue Forecast
Text size
Background

Collegium Pharmaceutical (NASDAQ: COLL) shares fell more than 13% in pre-market trading Tuesday after the company cut its full-year revenue forecast, raising concerns about its growth trajectory. The negative outlook overshadowed second-quarter financial results that beat analyst expectations on profit.

Guidance Cut Overshadows Earnings Beat

While Collegium reported adjusted earnings per share of $1.92, comfortably ahead of the consensus estimate of around $1.72, investors focused on the top-line performance and forward-looking statements. Second-quarter net revenue grew 6.3% year-over-year to $199.9 million but fell short of analyst projections, according to a report from Investing.com.

More significantly, the company trimmed its full-year revenue guidance. The midpoint of the new forecast came in approximately 3.4% below prior Wall Street estimates. For investors, a downward revision to future revenue often outweighs a beat on past earnings, as it can signal deteriorating business fundamentals.

Portfolio Performance Shows Mixed Picture

The revised outlook appears linked to continued challenges in the company's core pain management portfolio, which includes products like BELBUCA and Xtampza ER. This segment, which generated $140.9 million in the quarter, is facing persistent headwinds from generic competition.

Sample IUX Markets – In-articleAd

There were bright spots in the earnings report that failed to offset the guidance cut. Key growth drivers performed well:

  • JORNAY PM: Revenue for the ADHD treatment rose 41% year-over-year to $46.1 million.
  • AZSTARYS: The newly acquired asset contributed $12.9 million in its first partial quarter with the company.

Market Reaction

The pre-market drop of 13.2% pushed Collegium's stock price toward its 52-week low, erasing the gains accumulated since the company announced its acquisition of AZSTARYS. The sell-off was company-specific, occurring against a backdrop of a largely flat S&P 500, indicating that the move was a direct reaction to the earnings report and guidance rather than a broader market or sector trend.

Read next

More on Stocks
Back to latest news

LATEST